Current clinical approaches to combat resistance in lung adenocarcinoma include irreversible and mutant-selective inhibitors of EGFR, combination of cetuximab and afatinib [23] and combination of an EGFR inhibitor with a drug targeting a resistance pathway, such as the combination of gefitinib and a MET inhibitor [24]. Here, MET is linked to lung adenocarcinoma.